The burgeoning field of psychedelic medicine, which suffered a major setback last year when the Food and Drug Administration (FDA) rejected an application to approve the use of midomafetamine (MDMA) to treat post-traumatic...more
7/16/2025
/ Clinical Trials ,
Connecticut ,
FDA Approval ,
Healthcare ,
Life Sciences ,
Mental Health ,
Patient Access ,
Plant Based Products ,
Prescription Drugs ,
Schedule I Drugs ,
State Legislatures ,
Trump Administration